CHOP therapy combined with rituximab (R-CHOP) is currently a standard chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, relapse is detected despite R-CHOP in approximately 30% of patients. Treatment results should be further improved. Previously, second-and third-generation therapies such as MACOP-B, m-BACOD, and ProMACE-CytaBOM were performed to improve the results of DLBCL treatment. However, dose intensity (DI) enhancement increased treatmentassociated toxicity, and the treatment results did not improve. Recently, the entity of the relative dose intensity (RDI) was proposed as an index of the intensity of chemotherapy. In this method, the ratio of actual DI to the DI designed per specific period is numerically evaluated. The purpose of calculating the RDI is to achieve chemotherapy as scheduled while maintaining the DI, and not to improve the DI. Previous studies reported that the maintenance of the RDI during CHOP therapy improved the treatment results. In this paper, we review DI and RDI in studies of DLBCL, and revisit the significance of these indicators.
INTRODUCTION
There is a correlation between the dose of anti-tumor drugs and their therapeutic effects. These effects are thought to be particularly dependent on the amount of drug administered per unit time. "Dose intensity (DI)", which represents the amount (mg/m 2 ) of a drug administered per unit time (week), is used to evaluate the intensity of chemotherapy. This indicator is used mainly for tumors that are relatively sensitive to anti-tumor drugs and has been widely used in the treatment of malignant lymphoma.
An indicator called "relative dose intensity (RDI)" has also been proposed. 1 RDI reflects whether the DI of a therapy was implemented as planned, and is now commonly included in reports of clinical studies. RDI is a useful indicator for evaluating the feasibility of a drug therapy at a given strength. Multiple reports have also demonstrated a correlation between RDI and survival prognosis. [2] [3] [4] [5] [6] [7] [8] Therefore, even in daily practice, RDI is an indicator that one should be aware of.
In this paper, we review DI and RDI in studies of diffuse large B-cell lymphoma (DLBCL), and revisit the significance of these indicators.
INCREASE OF DOSE INTENSITY (DI) IN DLBCL THERAPIES
CHOP therapy (CHOP) is a combination chemotherapy of four drugs : cyclophosphamide (CPA), doxorubicin (ADM), vincristine (VCR), and prednisone (PSL). Although CHOP is a standard therapy for DLBCL, it has been unsuccessful in a substantial number of patients. Therefore, therapies superior to CHOP have been actively developed and studied. These therapies typically rely on increased DI.
Second-and third-generation chemotherapy regimens, such as m-BACOD, MACOP-B, and ProMACE-CytaBOM, were developed in the 1980s. These therapies involve many additional anti-cancer drugs. The third-generation chemotherapies attempt to increase DI by concentrating the administration of drugs in a short time period. Some excellent results were observed in phase II trials, 9-11 but third-generation therapies failed to show superiority to CHOP in a large-scale phase III trial. 12 A new therapy called CHOP-14 was developed in the 1990s, partly because granulocyte colony-stimulating factor (G-CSF) became available. CHOP-14 increases DI by shortening its treatment interval from 21 days (CHOP-21) to 14 days. A study conducted by the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) demonstrated the superiority of CHOP-14 to CHOP-21 in elderly patients. 13 This study compared four therapies : CHOP-14 and CHOP-21, as well as CHOEP-14 and CHOEP-21, which include etoposide. CHOP-14 was superior to CHOP-21 in complete remission rate, three-year event-free survival rate, and five-year overall survival rate. However, a similar study with young, low-risk patients showed that CHOEP-21 was superior.
14 Thus, the superiority of CHOP-14 is not yet clear. In the 2000s, R-CHOP, which is CHOP in combination with rituximab, an anti-CD20 chimeric antibody, has become a standard therapy for initial presentation of DLBCL. The superiority of CHOP-14 to CHOP-21 has not been demonstrated in combination with rituximab. In the 2009 American Society of Hematology meeting, a preliminary report was presented on LNH-03-6B, an ongoing clinical trial conducted by Groupe d'Etude des Lymphomes de l'Adulte (GELA). 15 This trial compares the efficacy of R-CHOP-14 with R-CHOP-21 in elderly DLBCL patients. In the preliminary analysis of 202 patients, the two-year progression-free survival rates were 49% for the R-CHOP-14 group and 63% for the R-CHOP-21 group, thus showing no statistically significant difference at that time (p＝0.1186). We are looking forward to the results of the final analysis of 602 cases.
High-dose chemotherapy plus autologous hematopoietic stem cell transplantation (HDC＋ASCT) has also been repeatedly explored as an approach to increase DI. However, similar to other chemotherapies with increased DI, the superiority of HDC＋ASCT in its efficacy for treating initial presentation cases is currently unclear. Multiple clinical trials to test HDC ＋ ASCT have been carried out. A typical example is the GOELAMS 072 trial that compared two therapies in patients younger than 60 years of age in the initial presentation stage of aggressive lymphoma. 16 Patients in the control group were treated eight times with standard CHOP. Patients in the test group were first treated with two rounds of CEEP (cyclophosphamide, epirubicin, vindesine, and prednisone) therapy. Those patients who exhibited better than partial response (PR) were then treated with MC (methotrexate and cytarabin) therapy, followed by HDC ＋ ASCT. Within the highintermediate risk group (HI) as defined by the International Prognostic Index (IPI), both the event-free survival rate (56% vs. 28% for test and control groups, respectively ; p＝0.003) and overall survival rate (74% vs. 44%, p＝0.001) were significantly higher for patients treated with HDC ＋ ASCT. Another trial, GOELAMS 075, was a phase II trial that tested the efficacy of HDC＋ASCT in combination with rituximab. It involved high-risk patients with initial presentation of DLBCL, and reported promising results. 17 We note, however, that many HDC＋ASCT clinical trials had been conducted before the introduction of rituximab. Some studies have shown negative results for HDC＋ASCT during the first remission of DLBCL in high-IPI-risk groups. 18, 19 Currently there is no consensus on the efficacy of HDC＋ASCT for initial presentation stages of DLBCL. Improvement in treatment results for DLBCL in high-risk patients is still hoped for even following the introduction of R-CHOP. The large-scale clinical trial S9704 is currently testing therapies with rituximab. Patients with a high risk of age-adjusted IPI are treated with eight rounds of R-CHOP or with six rounds of R-CHOP plus HDC＋ASCT.
RELATIVE DOSE INTENSITY (RDI) IN DLBCL THERAPIES
RDI represents the ratio of the amount of a drug actually administered (actual DI) to the amount planned (planned DI) for a fixed time period (Fig. 1) . 2 The purpose of calculating RDI is to evaluate whether or not the planned DI of a chemotherapy treatment was actually achieved.
RDI tends to remain satisfactory in most large-scale clinical trials. A typical example is the Mab Thera International Trial (MinT), in which young patients with low IPI risk scores were treated with a CHOP-like regimen either with or without rituximab. RDI was maintained at a median of 97% in both rituximab and non-rituximab groups. 20 The LNH 98-5 trial by GELA examined CHOP with and without rituximab in elderly patients. Although this trial did not use RDI as an indicator, at least 90% of the planned doses of CPA and ADM were administered for over 90% of the patients in both groups. 21 Other clinical trials of CHOP-like regimens have also shown well-maintained RDI, 22, 23 suggesting that a high RDI in CHOP-like regimens is relatively easy to maintain in a clinical trial setting.
In routine medical practice, however, drug doses may be reduced or the timing of administration may be postponed for various reasons including a patient's advanced age, organ damage, or complications such as infections. When chemotherapy is conducted on an outpatient basis, treatment intervals may become longer than planned because of a patient's social factors or calendar conflicts. Because routine medical 24 The results showed that the average RDI was approximately 80%. In 53% of the cases, an RDI of 85% or better could not be maintained. In 40% of the cases, the amount of drugs administered was reduced by at least 15%, and in 24% of the cases, the administration of drugs was delayed for 7 days or longer. The same report showed that with the progression of treatment cycles, an increasing number of cases failed to maintain an RDI of 85% or better. Among elderly patients in particular, the number of cases in which an RDI of 85% could not be maintained started to increase at early cycles.
RELATIONSHIP BETWEEN RDI AND SURVIVAL PROGNOSIS
It has been pointed out that maintenance of RDI is related to survival prognosis. Epelbaum et al. found that in CHOP treatment of patients with stage III-IV DLBCL, the prognosis deteriorated significantly when RDI of CPA fell below 70%. 2 Kwak et al. examined the relationship between prognosis and RDI of various drugs in 115 DLBCL patients treated by CHOP, m-BACOD, or MACOP-B therapies. Significantly worse prognoses were reported for cases with less than 75% RDI of ADM.
4 Table 1 shows a summary of the reports describing studies of the importance of maintaining RDI in CHOP. In every report, cases with a decreased RDI were found to have significantly deteriorated prognoses. The above studies were conducted without rituximab. It is unclear whether maintenance of RDI in chemotherapy is important even in combination with rituximab. Recently, we examined the relationship between RDI and survival prognosis in 152 incipient DLBCL cases, all treated by CHOP-like regimens in combination with rituximab. 25 For cases in which an average RDI (ARDI) of 70% could not be maintained, progression-free survival (PFS) (ARDIB70% vs. ARDI＜70% : 83.7 and 63.6%, respectively, p＝0.003) and overall survival (OS) (ARDIB70% vs. ARDI＜70% : 97.1 and 81.1%, respectively, p＝0.005) decreased significantly. The same data were further analyzed for two separate groups : patients classified (by IPI) as low and lowintermediate (L-LI group), and patients classified as high and high-intermediate (H-HI group). While a decline in ARDI did not appear to affect prognosis in the L-LI group (ARDIB70% vs. ARDI＜70% : PFS : 91.9 and 81.1%, respectively, p＝0.288, OS : 100 and 90.2%, respectively, p＝ 0.250), an inability to maintain ARDI at or above 70% resulted in a significant prognostic deterioration in the H-HI group (ARDIB70% vs. ARDI＜70% : PFS : 75.1 and 47. 2%, respectively, p ＝ 0.002, OS : 94.1 and 71.1%, respectively, p＝0.008). These results suggest the interesting possibility that the H-HI group may include more cases with a larger amount of tumors than the L-LI group, which may 
FACTORS AFFECTING RDI
As described above, however, routine practice involves different conditions than clinical trials, and maintaining a high RDI is not easy in daily practice. It is therefore important to understand the factors that may affect RDI prior to starting chemotherapy.
According to a large-scale investigation carried out by Lyman et al. in the US, several factors tend to lower RDI : age (over 60 years), disease stage (stage III or later), and a performance status (PS) of two or greater. 24 The factor that mitigates these RDI-lowering risks is the administration of prophylactic G-CSF. A study that we conducted included analysis of the following RDI-lowering factors : age (over 60 years), THP-COP therapy with rituximab (R-THP-COP), and febrile neutropenia (FN). 25 THP-COP therapy involves CHOP-like regimens and is applied for elderly persons in Japan. 26 In this regimen, tetrahydropyranyl adriamycin (THP-ADM), which exhibits reduced cardiac toxicity, was used instead of ADM, and the doses of CPA and VCR were decreased. Prophylactic use of G-CSF mitigates these risks of RDI reduction. Taken together, these results suggest that administration of prophylactic G-CSF might be useful in daily practice for maintaining a high RDI when treating a DLBCL patient with the above risk factor(s).
The American Society of Clinical Oncology (ASCO) recommends primary use of prophylactic G-CSF for patients with a risk of developing FN of 20% or higher, and secondary use of prophylactic G-CSF for patients who experience complications accompanying neutropenia (such as FN from a prior cycle of chemotherapy), and for whom a dose reduction in the next cycle may compromise the prognosis. 27 Even when the risk of developing FN due to the therapy itself is less than 20%, the guidelines recommend that prophylactic use of G-CSF is appropriate for patients with an increased risk of developing FN for other reasons, such as advanced age (65 or older), past history of FN, or unfavorable performance status. A meta-analysis also showed that prophylactic G-CSF significantly lowers the risk not only of developing FN, but also of early death including infection-related death. 28 Use of prophylactic G-CSF should be considered for cases with an increased risk of developing FN to lower the risk of early death as well as to maintain a high RDI.
CONCLUSION
R-CHOP has improved treatment results for patients in initial presentation of DLBCL. Among high-risk patients, however, further improvement is necessary. We hope to see the development of therapies with increased DI for the highrisk group, by means of stratifying and isolating high-risk cases using IPI or other categorizations. Even in combination with rituximab, patients with lowered RDI have an unsatisfactory prognosis. For patients at risk of RDI decline, it is important to implement measures, such as prophylactic use of G-CSF, in order to minimize the decline in RDI.
